SDOI: South Danish Obesity Initiative, Screening for Unrecognized Obesity Related Disease

Sponsor
Claus Bogh Juhl (Other)
Overall Status
Recruiting
CT.gov ID
NCT05176132
Collaborator
Steno Diabetes Center Odense (Other), Odense University Hospital (Other)
2,700
1
120
22.5

Study Details

Study Description

Brief Summary

People with BMI >30 kg/m2 will be included in at population-based cohort. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included. All participants with age 18 and 60 years.

To evaluate health status participants will be screened by for undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, polycystic ovary syndrome (PCOS), and joint pain and for quality of life at baseline, 1 year, and 5 years. Additionally, anthropometric measurements are collected and a biobank is established for future research studies.

People with obesity related disease will be offered participation in a 12 month personalized lifestyle intervention program aimed at improvement of health and self-perception.

The collected data will be used to detect the prevalence for obesity-related disease to identify predictors for future obesity related disease and to evaluate the effect of a lifestyle intervention on health and quality of life.

Condition or Disease Intervention/Treatment Phase
  • Other: Life style intervention (dietician+ physiotherapist)
  • Other: Self management
  • Other: No intervention

Detailed Description

Obesity is associated with a variety of adverse health problems, and there is currently no effective scalable treatment with a durable effect. Additionally, well-known obesity related health problems are often underdiagnosed.

A Danish cohort of people with BMI >30 kg/m2 is established on University Hospital South West Jutland. Additionally, one control group with BMI 18.5-25 kg/m2 and one control group with BMI 25-30 kg/m2 will be included. Age range is defined as 18 and 60 years.

To evaluate health status all participants are screened by for undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, polycystic ovary syndrome (PCOS) and joint pain.

Data will be collected from questionnaires (Impact of Weight related on Quality of Life, Attitude to physical activity questionnaire, Adult Eating Behavior questionnaire, Berlin sleep apnea and Epworths Sleepiness scale, PCOS related questionnaire including Ferriman-Gallwey score, Work Ability Index, and weight history); clinical laboratory variables (HbA1c, glucose, c-peptide, lipid status, thyroid stimulating hormone (TSH), triiodothyronine (T3), thyroxine (T4), hemoglobin, thrombocytes, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), bilirubin, gamma glutamic transferase, lactate dehydrogenase (LDH), alkaline phosphatase, and creatinine levels); and anthropometric measurements (blood pressure, EKG, liver elastography, spirometry (forced expiratory volume during first second as a fraction of forced vital capacity (FEV1/FVC), hand grip strength, gait speed, and CT scan for estimation of the subcutaneous and visceral fat volume). People with diseases uncovered by the screening program will be referred to specialized departments or general practice for further assessment and treatment.

A biobank (blood, feces, urine) is established for future research studies. Patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dietitians and physiotherapists focusing on health improvement through personal motivation, perceived limitations and body accept. Additionally, participants are invited to a 1 year follow-up. All participants, independent of disease status, will be invited for at new screening 5 years after the initial visit.

The data collected for the cohort will be used to estimate the prevalence and development of new obesity-related diseases, and to identify predictors for obesity-related diseases. Finally, the effect of the lifestyle intervention-program will be evaluated.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
2700 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
South Danish Obesity Initiative (SDOI)
Actual Study Start Date :
Sep 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2030

Arms and Interventions

Arm Intervention/Treatment
OBESE (BMI>30)

BMI above 30 kg/m2 and being 18 to 60 years of age. Since the initiative is open for the general obese population, the investigators did not define the size of the cohort, but expect around 500 referrals per year.

Other: Life style intervention (dietician+ physiotherapist)
Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.

Other: Self management
Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)

CONTROL Normal weight (BMI 20-25)

100 persons with normal weight (BMI 20 - 25 kg/m2) 18 to 60 years of age

Other: No intervention
Control groups (BMI 20-25 and BMI 25-30)

CONTROL Overweight (BMI 25-30)

100 persons with overweight (BMI 25 - 30 kg/m2) 18 to 60 years of age

Other: No intervention
Control groups (BMI 20-25 and BMI 25-30)

Outcome Measures

Primary Outcome Measures

  1. Prevalence of unrecognized obesity-related diseases [Baseline]

    Undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, and polycystic ovary syndrome (PCOS).

  2. Prevalence of unrecognized obesity-related diseases [5 years]

    Undetected obesity-related diseases (hypertension, diabetes, dyslipidemia, sleep apnea, non-alcoholic fatty liver disease, chronic obstructive pulmonary disease, EKG-abnormalities, and polycystic ovary syndrome (PCOS).

Secondary Outcome Measures

  1. Consultation systolic and diastolic blood pressure [Baseline]

    Standard cut-of values

  2. Consultation systolic and diastolic blood pressure [1 year]

    Standard cut-of values

  3. Consultation systolic and diastolic blood pressure [5 years]

    Standard cut-of values

  4. 24 hour blood pressure [Baseline]

    Measures mean blood pressure, day and night

  5. 24 hour blood pressure [5 years]

    Measures mean blood pressure, day and night

  6. HbA1c [Baseline]

    HbA1c equal to or higher than 48 mmol/mol indicates diabetes

  7. HbA1c [1 year]

    HbA1c equal to or higher than 48 mmol/mol indicates diabetes

  8. HbA1c [5 years]

    HbA1c equal to or higher than 48 mmol/mol indicates diabetes

  9. Prediabetes [Baseline]

    Hba1c 43-47 indicates prediabetes

  10. Prediabetes [1 year]

    Hba1c 43-47 indicates prediabetes

  11. Prediabetes [5 years]

    Hba1c 43-47 indicates prediabetes

  12. Low density lipoprotein [Baseline]

    Dyslipidemia is defined as low density lipoprotein (LDL) > 3 mmol/l or high density lipoprotein (HDL) cholesterol < 1 mmol/l.

  13. Low density lipoprotein [1 year]

    Dyslipidemia is defined as low density lipoprotein (LDL) > 3 mmol/l or high density lipoprotein (HDL) cholesterol < 1 mmol/l.

  14. Low density lipoprotein [5 years]

    Dyslipidemia is defined as low density lipoprotein (LDL) > 3 mmol/l or high density lipoprotein (HDL) cholesterol < 1 mmol/l.

  15. Berlin sleep apnea questionnaire [Baseline]

    Berlin sleep apnea questionnaire: The Berlin Questionnaire consists of three categories designed to elicit information regarding snoring (category 1), daytime somnolence (category 2), and the presence of obesity and/or hypertension (category 3). Categories 1 and 2 are considered positive if 2 or more responses are positive category 3 is considered positive if 1 response is positive and/or the body mass index is greater than 30 kg per meter squared. A patient is considered to have a high likelihood of sleep disordered breathing if 2 or more categories are positive.

  16. Berlin sleep apnea questionnaire [5 years]

    Berlin sleep apnea questionnaire: The Berlin Questionnaire consists of three categories designed to elicit information regarding snoring (category 1), daytime somnolence (category 2), and the presence of obesity and/or hypertension (category 3). Categories 1 and 2 are considered positive if 2 or more responses are positive category 3 is considered positive if 1 response is positive and/or the body mass index is greater than 30 kg per meter squared. A patient is considered to have a high likelihood of sleep disordered breathing if 2 or more categories are positive.

  17. Epworth Sleepiness Scale [Baseline]

    Epworth Sleepiness Scale: Score 0-24. 0-5 Lower Normal Daytime Sleepiness, 6-10 Higher Normal Daytime Sleepiness, 11-12 Mild Excessive Daytime Sleepiness 13-15 Moderate Excessive Daytime Sleepiness, 16-24 Severe Excessive Daytime Sleepiness

  18. Epworth Sleepiness Scale [5 years]

    Epworth Sleepiness Scale: Score 0-24. 0-5 Lower Normal Daytime Sleepiness, 6-10 Higher Normal Daytime Sleepiness, 11-12 Mild Excessive Daytime Sleepiness 13-15 Moderate Excessive Daytime Sleepiness, 16-24 Severe Excessive Daytime Sleepiness

  19. Apnea hypopnoea index (AHI) [Baseline]

    Quantifies sleep apnea cardiorespiratory monitoring: AHI < 5 per hour=normal or minimal, AHI ≥ 5, but < 15 per hour: mild, AHI ≥ 15, but < 30 per hour moderate and AHI ≥ 30 per hour: severe

  20. Apnea hypopnoea index (AHI) [5 years]

    Quantifies sleep apnea cardiorespiratory monitoring: AHI < 5 per hour=normal or minimal, AHI ≥ 5, but < 15 per hour: mild, AHI ≥ 15, but < 30 per hour moderate and AHI ≥ 30 per hour: severe

  21. Elastography [Baseline]

    Quantifies liver-stiffness as a measure of non-alcoholic fatty liver disease, lower is better

  22. Elastography [5 years]

    Quantifies liver-stiffness as a measure of non-alcoholic fatty liver disease, lower is better

  23. FEV1/FVC [Baseline]

    Indication of Chronic obstructive pulmonary disease as measured by spirometry

  24. FEV1/FVC [5 years]

    Indication of Chronic obstructive pulmonary disease as measured by spirometry

  25. EKG [Baseline]

    Under resting conditions, standard 12 lead electrocardiography

  26. EKG [5 years]

    Under resting conditions, standard 12 lead electrocardiography

  27. Ferriman-Gallwey score self-reported [Baseline]

    Measures hirsutism and indicates risk of Polycystic ovary syndrome (PCOS): Whole body equal or less than 10: normal, over 10: increased, Face: more than 2 is considered high and indicates hirsutism

  28. Ferriman-Gallwey score self-reported [5 years]

    Measures hirsutism and indicates risk of Polycystic ovary syndrome (PCOS): Whole body equal or less than 10: normal, over 10: increased, Face: more than 2 is considered high and indicates hirsutism

  29. Hand-grip force [Baseline]

    Handgrip force: Higher is better, no defined cut-off value

  30. Hand-grip force [1 year]

    Handgrip force: Higher is better, no defined cut-off value

  31. Hand-grip force [five years]

    Handgrip force: Higher is better, no defined cut-off value

  32. Fat-free mass [Baseline]

    Fat-free mass as estimated by bioimpedance measure, higher is better, no cut-of value

  33. Fat-free mass [1 year]

    Fat-free mass as estimated by bioimpedance measure, higher is better, no cut-of value

  34. Fat-free mass [5 years]

    Fat-free mass as estimated by bioimpedance measure, higher is better, no cut-of value

  35. Gait-speed [Baseline]

    Gait Speed in 6 meters: High more than 1.1 m/s, Median 0.7-1.1 m/s, Low <0.7 m/s

  36. Gait-speed [1 year]

    Gait Speed in 6 meters: High more than 1.1 m/s, Median 0.7-1.1 m/s, Low <0.7 m/s

  37. Gait-speed [5 years]

    Gait Speed in 6 meters: High more than 1.1 m/s, Median 0.7-1.1 m/s, Low <0.7 m/s

  38. Body weight [Baseline]

    Participants are weighed in light clothes with no shoes or pocket items, lower is better

  39. Body weight [1 year]

    Participants are weighed in light clothes with no shoes or pocket items, lower is better

  40. Body weight [5 years]

    Participants are weighed in light clothes with no shoes or pocket items, lower is better

  41. BMI [Baseline]

    Body weight / m2, lower is better

  42. BMI [1 year]

    Body weight / m2, lower is better

  43. BMI [5 years]

    Body weight / m2, lower is better

  44. Waist circumference [Baseline]

    Lower is better

  45. Waist circumference [1 year]

    Lower is better

  46. Waist circumference [5 years]

    Lower is better

  47. Work-ability Index [Baseline]

    Measures the ability of a person to work, higher values are better, no cut-of value

  48. Work-ability Index [5 years]

    Measures the ability of a person to work, higher values are better, no cut-of value

  49. Impact of weight on quality of life-lite [Baseline]

    Measures weight associated quality of life, higher values are better, no cut-of value

  50. Impact of weight on quality of life-lite [1 year]

    Measures weight associated quality of life, higher values are better, no cut-of value

  51. Impact of weight on quality of life-lite [5 years]

    Measures weight associated quality of life, higher values are better, no cut-of value

  52. Adult Eating Behavior Questionnaire [Baseline]

    Measures eating behavior and appetite traits, descriptive

  53. Adult Eating Behavior Questionnaire [1 year]

    Measures eating behavior and appetite traits, descriptive

  54. Adult Eating Behavior Questionnaire [5 years]

    Measures eating behavior and appetite traits, descriptive

  55. SDOI attitude to physical activity questionnaire [baseline]

    Measures a persons attitude to physical activity, higher is better, no cut-of value

  56. SDOI attitude to physical activity questionnaire [1 year]

    Measures a persons attitude to physical activity, higher is better, no cut-of value

  57. SDOI attitude to physical activity questionnaire [5 years]

    Measures a persons attitude to physical activity, higher is better, no cut-of value

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI >30 (Obese cohort), BMI 20-25 (control group I), BMI 25-30 (control group II)

  • Age 18-60 years

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital of South West Jutland, University hospital of Southern Denmark Esbjerg Denmark 6700

Sponsors and Collaborators

  • Claus Bogh Juhl
  • Steno Diabetes Center Odense
  • Odense University Hospital

Investigators

  • Principal Investigator: Claus B Juhl, Prof. PhD MD, Hospital South West Jutland, University hospital of Southern Denmark

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Claus Bogh Juhl, Professor, MD, PhD, Hospital of South West Jutland
ClinicalTrials.gov Identifier:
NCT05176132
Other Study ID Numbers:
  • SDOI
First Posted:
Jan 4, 2022
Last Update Posted:
Jan 20, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Claus Bogh Juhl, Professor, MD, PhD, Hospital of South West Jutland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 20, 2022